Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from Biotron ( (AU:BIT) ).
Biotron Limited has completed its non-renounceable rights issue, raising $645,861 through the issue of 215,286,751 fully paid ordinary shares and 107,643,345 options, which will trade on the ASX under the code BITO. The capital will fund toxicology studies and small-scale production of its HBV drug, support ongoing antiviral R&D, cover patent and commercialisation expenses across its portfolio, and provide working capital, while a remaining shortfall of $878,733 is backed by a subscription commitment from Peak Asset Management with the final date to issue shortfall shares set for 12 March 2026.
More about Biotron
Biotron Limited is an Australian biotechnology company focused on developing antiviral therapies, including a lead program targeting Hepatitis B virus (HBV). Its activities span drug discovery, toxicology, process development, scale-up manufacturing, patent portfolio management and commercialisation of its antiviral drug candidates.
YTD Price Performance: -38.89%
Technical Sentiment Signal: Sell
Current Market Cap: A$5.48M
For detailed information about BIT stock, go to TipRanks’ Stock Analysis page.